Skip to content
Screener

Revvity RVTY Cash & Equivalents

Cash & Equivalents at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$4.06B-11.7%
Danaher logo
DanaherDHR
$4.35B+47.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$139M+19.6%
WAT
Waters CorporationWAT
$539M+46.8%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%
Illumina logo
IlluminaILMN
$1.04B+11.3%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$12.83B+28.7%
Enterprise value$15.91B+28.6%
P/E53.5×+18.6×
P/S4.4×+0.9×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000031791-26-000019
Line itemThree Months Ended / April 5,2026Three Months Ended / March 30,2025
Net decrease in cash, cash equivalents and restricted cash(59,564)(25,765)
Cash, cash equivalents and restricted cash at beginning of period921,0301,164,452
Cash, cash equivalents and restricted cash at end of period$861,466$1,138,687
Supplemental disclosures of cash flow information
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total shown in the condensed consolidated statements of cash flows:
Cash and cash equivalents$860,320$1,137,620
Restricted cash included in other current assets4281,067
Restricted cash included in other assets718

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's cash & equivalents?
Revvity (RVTY) reported cash & equivalents of $861.47M in Q1 2026.
How has Revvity's cash & equivalents changed year-over-year?
Revvity's cash & equivalents decreased by 24.3% year-over-year, from $1.14B to $861.47M.
What is the long-term trend for Revvity's cash & equivalents?
Over 5 years (2020 to 2025), Revvity's cash & equivalents has grown at a 18.0% compound annual growth rate (CAGR), from $402.61M to $921.03M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Revvity's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude